Drugs / BH-30643
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06706076 | Jan 2025 → Jan 2029 expected | non-small cell lung carcinoma | BlossomHill Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BH-30643 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06706076 ↗ |
| Action | Inhibit | “BH-30643 is a novel, orally available, non-covalent, macrocyclic, mutant selective OMNI-EGFR inhibitor that targets a broad diversity of mutations in the EGFR kinase domain.” NCT06706076 ↗ |
| Route | Oral | “Subjects will take BH-30643 orally depending on their dose level assignment.” NCT06706076 ↗ |
| Target | EGFR | “BH-30643 is a novel, orally available, non-covalent, macrocyclic, mutant selective OMNI-EGFR inhibitor that targets a broad diversity of mutations in the EGFR kinase domain.” NCT06706076 ↗ |